{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:05:26Z","timestamp":1753891526786,"version":"3.41.2"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Acute megakaryocytic leukemia (AMKL) constitutes a rare subtype of acute myeloid leukemia in clinical practice and exhibits a high degree of heterogeneity. This study endeavors to explore the clinical manifestations, diagnosis, treatment, and prognosis of AMKL, offering novel perspectives for both basic and clinical investigations of rare myeloid tumors in the fields of oncology and hematology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinical data of 23 patients with AMKL admitted to the Fujian Medical University Union Hospital, the Affiliated Hospital of Putian University, and the First Affiliated Hospital of Gannan Medical University from January 2014 to July 2024 were retrospectively analyzed. The clinical characteristics, diagnosis and differential diagnosis, treatment, and prognosis of AMKL patients were examined. Additionally, the latest literature in the PubMed database was retrieved for review and discussion regarding the research advancements of AMKL and its diagnosis and treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 23 patients with AMKL were encompassed in this study, the clinical manifestations of all patients were predominantly hematological non-specific symptoms, such as anemia, bleeding, infection, and invasive swelling or occupation of tissues and organs. All patients underwent bone marrow puncture biopsy, cytochemical staining of bone marrow cells of AMKL patients demonstrated that the staining of POX, NAS-DCE, and hot brine test were negative, however, the PAS staining, <jats:italic>\u03b1<\/jats:italic>-NAE staining and NaF inhibition test were positive. Except for 2 patients who were not detected by flow immunotyping, cytogenetics and molecular biology, the remaining 21 patients were detected accordingly, and megakaryocyte antigens (CD41, CD42, CD61) were expressed in these 21 patients with AMKL, accompanied by certain cytogenetic or molecular biological abnormalities. There were two patients forsook treatment in our study, and remaining 21 patients who underwent clinical treatment measures, 1 patient (4.76%) died after 1 course of chemotherapy, 3 patients (14.29%) succumbed to severe infection occasioned by bone marrow suppression after 2 courses of chemotherapy, and 7 patients (33.33%) achieved CR after 1 course of chemotherapy, 4 patients (19.05%) attained CR after 2 courses of chemotherapy, and 6 patients (28.57%) failed to achieve remission (NR) after 2 courses of induction chemotherapy. Correspondingly, a total of 6 patients received allogeneic hematopoietic stem cell transplantation (HSCT) in this study, among which 3 patients received HSCT after CR in the first induction chemotherapy, 1 patient received HSCT after CR in the second round of induction chemotherapy, and 2 patients with NR after induction chemotherapy underwent HSCT. We conducted follow-up until July 31, 2024 and discovered that among the 17 patients who received complete and standardized treatment and survived, 3 (17.65%) patients were lost to follow-up and 8 (47.06%) patients perished within 2\u202fyears due to treatment failure attributed to disease progression, recurrence, and uncontrollable disease. The remaining 6 patients (35.29%) are still alive at present and have not experienced disease progression or recurrence. The median follow-up period was 33.5\u202fmonths (ranging from 4.5 to 76\u202fmonths) as of July 31, 2024, the results of survival analysis indicate: the OS and EFS of AMKL patients treated with chemotherapy alone were inferior to those treated with chemotherapy combined with HSCT (all <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05). Additionally, AMKL patients with severely abnormal cytogenetic test results had poorer OS and EFS (all <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05). Concurrently, the OS and EFS of AMKL patients who achieved CR after 2 courses of induction chemotherapy were significantly superior to those of AMKL patients who did not achieve CR (all <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>AMKL is infrequent in clinical practice, features a poor prognosis, lacks specificity in clinical manifestations, and is prone to misdiagnosis or omission. Clinical trials of new drugs should be prioritized, while close monitoring of measurable residual disease (MRD) should be implemented. Patients with AMKL might benefit from induced remission chemotherapy combined with novel targeted therapy. Hematopoietic stem cell transplantation should be carried out as soon as possible after the first CR induced by standard chemotherapy to optimize the prognosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1574132","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:23:19Z","timestamp":1749187399000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel perceptions and insights into the rare hematologic malignancy of acute megakaryocytic leukemia: a multicenter clinical retrospective study"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanquan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiachen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huidong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.2147\/OTT.S146973","article-title":"Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 BCR-ABL transcripts","volume":"10","author":"Dima","year":"2017","journal-title":"Onco Targets Ther"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1182\/blood-2015-05-567859","article-title":"The biology of pediatric acute megakaryoblastic leukemia","volume":"126","author":"Gruber","year":"2015","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1170622","DOI":"10.3389\/fcell.2023.1170622","article-title":"Advances in molecular characterization of pediatric acute megakaryoblastic leukemia not associated with down syndrome; impact on therapy development","volume":"11","author":"Li","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"940725","DOI":"10.3389\/fonc.2022.940725","article-title":"Pediatric non-Down\u2019s syndrome acute megakaryoblastic leukemia patients in China: a single center\u2019s real-world analysis","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"636633","DOI":"10.3389\/fonc.2021.636633","article-title":"Molecular mechanisms of the genetic predisposition to acute Megakaryoblastic leukemia in infants with down syndrome","volume":"11","author":"Grimm","year":"2021","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.11855\/j.issn.0577-7402.2022.10.1006","article-title":"Clinical analysis and literature review of 14 patients with acute megakaryocytic leukemia","volume":"47","author":"Liu","year":"2022","journal-title":"Med J Chin PLA"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000227842","article-title":"A comprehensive set of idiograms representing all interpretive levels of resolution: ISCN (2009)","volume":"125","author":"Chia","year":"2009","journal-title":"Cytogenet Genome Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/s41417-020-00262-9","article-title":"SON inhibits megakaryocytic differentiation via repressing RUNX1 and the megakaryocytic gene expression program in acute megakaryoblastic leukemia","volume":"28","author":"Vukadin","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1111\/bph.14031","article-title":"Tetrandrine antagonizes acute megakaryoblastic leukaemia growth by forcing autophagy-mediated differentiation","volume":"174","author":"Liu","year":"2017","journal-title":"Br J Pharmacol"},{"key":"ref14","first-page":"679","article-title":"Uber einen fall von akuter megakaryocyblasten-leukamie, zugleich einige bemerkungen zum Problem der akuten leukemie[J]","volume":"118","author":"Von Boros","year":"1931","journal-title":"Z Klin Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood.V51.1.45.45","article-title":"Megakaryoblastic acute leukemia: identification by the ultrastructural demonstration of platelet peroxidase[J]","volume":"51","author":"Breton-Gorius","year":"1978","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.7326\/0003-4819-103-3-460","article-title":"Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British cooperative group","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann Intern Med"},{"key":"ref17","first-page":"272","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2231731","DOI":"10.1080\/16078454.2023.2231731","article-title":"Analysis 33 patients of non-DS-AMKL with or without acquired trisomy 21 from multiple centers and compared to 118 AML patients","volume":"28","author":"Zhang","year":"2023","journal-title":"Hematology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3390\/cancers14061583","article-title":"Immunophenotypic analysis of acute Megakaryoblastic leukemia: a EuroFlow study","volume":"14","author":"Brouwer","year":"2022","journal-title":"Cancers"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1182\/blood-2017-01-764324","article-title":"Improved outcomes for myeloid leukemia of down syndrome: a report from the Children\u2019s oncology group AAML0431 trial","volume":"129","author":"Taub","year":"2017","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1002\/cncr.27484","article-title":"Favorable survival maintained in children who have myeloid leukemia associated with down syndrome using reduced-dose chemotherapy on Children\u2019s oncology group trial A2971: a report from the Children\u2019s oncology group","volume":"118","author":"Sorrell","year":"2012","journal-title":"Cancer"},{"volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","year":"2017","author":"Swerdlow","key":"ref22"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1182\/blood-2017-01-765057","article-title":"Therapy reduction in patients with down syndrome and myeloid leukemia: the international ML-DS 2006 trial","volume":"129","author":"Uffmann","year":"2017","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bcmd.2013.07.008","article-title":"The impact of trisomy 21 on foetal haematopoiesis","volume":"51","author":"Roberts","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1080\/10428194.2021.1907377","article-title":"Acute megakaryoblastic leukemia with a novel GATA1 mutation in a second trimester stillborn fetus with trisomy 21","volume":"62","author":"Bonometti","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3760\/cma.j.issn.0253-2727.2016.04.010","article-title":"Analysis on the laboratory examination characteristics in 22 patients with acute megakaryoblastic leukemia[J]","volume":"37","author":"Dong","year":"2016","journal-title":"Chin J Hematol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"6988","DOI":"10.3892\/ol.2018.9501","article-title":"Clinical diagnosis of adult patients with acute megakaryocytic leukemia","volume":"16","author":"Zhao","year":"2018","journal-title":"Oncol Lett"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/1097-0142(19920715)70:2<451::aid-cncr2820700213>3.0.co;2-v","article-title":"Ultrastructural and ultracytochemical differences between megakaryoblastic leukemia in children and adults. Analysis of 49 patients","volume":"70","author":"Eguchi","year":"1992","journal-title":"Cancer"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1365-2141.2011.08948.x","article-title":"Molecular lesions in childhood and adult acute megakaryoblastic leukaemia","volume":"156","author":"Hama","year":"2012","journal-title":"Br J Haematol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"a034884","DOI":"10.1101\/cshperspect.a034884","article-title":"Acute megakaryocytic leukemia","volume":"10","author":"McNulty","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/j.clml.2020.11.001","article-title":"Outcome and prognostic features in pediatric acute Megakaryoblastic leukemia without down syndrome: a retrospective study in China","volume":"21","author":"Wang","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3390\/ph16111614","article-title":"A review of childhood acute myeloid leukemia: diagnosis and novel treatment","volume":"16","author":"Tseng","year":"2023","journal-title":"Pharmaceuticals"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bjh.15725","article-title":"CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity","volume":"184","author":"Masetti","year":"2019","journal-title":"Br J Haematol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"8747","DOI":"10.1038\/s41467-024-53158-9","article-title":"CBFA2T3-GLIS2 mediates transcriptional regulation of developmental pathways through a gene regulatory network","volume":"15","author":"Garfinkle","year":"2024","journal-title":"Nat Commun"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"113084","DOI":"10.1016\/j.celrep.2023.113084","article-title":"CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to navitoclax","volume":"42","author":"Neault","year":"2023","journal-title":"Cell Rep"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1084\/jem.20121343","article-title":"Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models","volume":"209","author":"Thiollier","year":"2012","journal-title":"J Exp Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-017-0396-0","article-title":"Hh\/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene","volume":"10","author":"Masetti","year":"2017","journal-title":"J Hematol Oncol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e157101","DOI":"10.1172\/JCI157101","article-title":"CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target","volume":"132","author":"Le","year":"2022","journal-title":"J Clin Invest"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1182\/bloodadvances.2019030981","article-title":"Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities","volume":"3","author":"Cardin","year":"2019","journal-title":"Blood Adv"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1441318","DOI":"10.3389\/fonc.2024.1441318","article-title":"Liver fibrosis among infants with t(1;22)(p13;q13) acute megakaryoblastic leukemia: a case report and literature review","volume":"14","author":"Arad-Cohen","year":"2024","journal-title":"Front Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e30251","DOI":"10.1002\/pbc.30251","article-title":"Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: a report from the Children\u2019s oncology group","volume":"70","author":"Chisholm","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e11331","DOI":"10.1097\/MD.0000000000011331","article-title":"Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: a case report of a CARE-compliant article","volume":"97","author":"Ding","year":"2018","journal-title":"Medicine"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1182\/blood.2019003928","article-title":"CML in megakaryocytic transformation and extramedullary infiltration","volume":"135","author":"Kagotho","year":"2020","journal-title":"Blood"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e14842","DOI":"10.1111\/ped.14842","article-title":"Therapy-related acute megakaryoblastic leukemia with severe myelofibrosis","volume":"64","author":"Yoshino","year":"2022","journal-title":"Pediatr Int"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1116205","DOI":"10.3389\/fonc.2023.1116205","article-title":"Unmanipulated haploidentical hematopoietic stem cell transplantation for pediatric de novo acute megakaryoblastic leukemia without down syndrome in China: a single-center study","volume":"13","author":"Huang","year":"2023","journal-title":"Front Oncol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1182\/blood-2013-05-503011","article-title":"Development of acute megakaryoblastic leukemia in down syndrome is associated with sequential epigenetic changes","volume":"122","author":"Malinge","year":"2013","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e68601","DOI":"10.1371\/journal.pone.0068601","article-title":"Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic leukemia","volume":"8","author":"Caldwell","year":"2013","journal-title":"PLoS One"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2169\/internalmedicine.9005-17","article-title":"Acute Megakaryoblastic leukemia developing as donor cell leukemia after umbilical cord blood transplantation","volume":"57","author":"Adachi","year":"2018","journal-title":"Intern Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.leukres.2016.04.017","article-title":"Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT","volume":"47","author":"Ishiyama","year":"2016","journal-title":"Leuk Res"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/MPH.0000000000002822","article-title":"Clinical analysis of pediatric acute megakaryocytic leukemia with CBFA2T3-GLIS2 fusion gene","volume":"46","author":"Du","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/ng.3772","article-title":"Pediatric non-down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes","volume":"49","author":"De Rooij","year":"2017","journal-title":"Nat Genet"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/gcc.22444","article-title":"Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-down syndrome","volume":"56","author":"Hara","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1111\/jcmm.17810","article-title":"Design and preclinical testing of an anti-CD41 CAR T cell for the treatment of acute megakaryoblastic leukaemia","volume":"27","author":"Tigu","year":"2023","journal-title":"J Cell Mol Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.htct.2023.09.2364","article-title":"Immunophenotypic markers for the evaluation of minimal\/measurable residual disease in acute megakaryoblastic leukemia","volume":"46","author":"Pinto","year":"2024","journal-title":"Hematol Transfus Cell Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1574132\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:23:22Z","timestamp":1749187402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1574132\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":54,"alternative-id":["10.3389\/fmed.2025.1574132"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1574132","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"article-number":"1574132"}}